| Company Name: |
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
|
| Tel: |
17702719238 |
| Email: |
sales@sun-shinechem.com |
| Products Intro: |
Product Name:Bomedemstat; IMG-7289 CAS:1990504-34-1 Purity:98% HPLC Package:50.0mg;100.0mg; 200.0mg;500mg;1g;5g; 10g
|
Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- manufacturers
- Bomedemstat
-
- $411.00
-
2026-07-06
- CAS:1990504-34-1
- Purity: 98.07%
- Supply Ability: 10g
|
| | Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- Basic information |
| Product Name: | Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- | | Synonyms: | Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)-;IMG-7289 (free base);N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)-Benzamide | | CAS: | 1990504-34-1 | | MF: | C28H34FN7O2 | | MW: | 519.61 | | EINECS: | | | Product Categories: | | | Mol File: | 1990504-34-1.mol | ![Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- Structure](CAS/20210111/GIF/1990504-34-1.gif) |
| | Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- Chemical Properties |
| density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (192.45 mM; Need ultrasonic) | | pka | 13.08±0.46(Predicted) | | form | Oil | | color | Colorless to light yellow |
| | Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- Usage And Synthesis |
| Uses | Bomedemstat is a styrenylcyclopropylamine LSD1 inhibitor, and an antitumor agent. | | in vivo | Bomedemstat treatment (oral gavage; 45 mg/kg; once daily; 56 d) normalizes or improves blood cell counts, reduces spleen volumes, restores normal splenic architecture, and reduces bone marrow fibrosis[1]. | Animal Model: | Mx-Jak2V617F mice[1] | | Dosage: | 45mg/kg | | Administration: | Oral gavage; 45mg/kg; once daily; 56 days | | Result: | Reduced splenomegaly significantly with a few treated mice normalizing their spleen weight, the 56-day course led to partial restoration of lymph follicles and spleen architecture by histological examination. |
| | IC 50 | KDM1/LSD1 |
| | Benzamide, N-[(1S)-4-[[(1R,2S)-2-(4-fluorophenyl)cyclopropyl]amino]-1-[(4-methyl-1-piperazinyl)carbonyl]butyl]-4-(1H-1,2,3-triazol-1-yl)- Preparation Products And Raw materials |
|